# Johnson & Johnson (jnj)

Generated: `2026-02-05T22:12:41Z`

- Assets: **17**
- Assets with linked trials: **5**
- Trials: **41**

## Top assets

| Asset | Highest stage | Linked trials | Example indications |
|---|---:|---:|---|
| Azacitidine | Registration | 4 | Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7) |
| RYBREVANT | Phase 3 | 27 | Frontline Non Small chemotherapy (PAPILLON) Bleximenib Newly Diagnosed AML, with Venetoclax and ERLEADA (apalutamide) ASCT Localized Prostate |
| INLEXZO | Phase 3 | 5 | High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination |
| JNJ-7446 | Phase 3 | 2 | Lung Cancer |
| JNJ-8543 | Phase 3 | 0 | Hematological Malignancies |
| JNJ-4804 Co-antibody | Phase 3 | 0 | Psoriatic Arthritis nipocalimab​ Systemic Lupus; Crohn's Disease nipocalimab​ Idiopathic Inflammatory |
| JNJ-4681 | Phase 3 | 0 | Hematological Malignancies |
| JNJ-3413 | Phase 3 | 0 | Lymphoma |
| JNJ-2175 | Phase 3 | 0 | Solid Tumors |
| JNJ-1887 sCD59 | Phase 3 | 0 | Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics |
| JNJ-1900 | Phase 1 | 2 | Lung Cancer |
| JNJ-8377 | Phase 1 | 0 | Lymphoma |
| JNJ-5322 | Phase 1 | 0 | Multiple Myeloma |
| JNJ-5120 | Phase 1 | 0 | Major Depressive |
| JNJ-4680 | Phase 1 | 0 | Lung Cancer |
| JNJ-2761 | Phase 1 | 0 | Multiple Myeloma |
| JNJ-1493 | Phase 1 | 0 | Hematological |